Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years

Lin, Shujuan; Gao, Kai; Gu, Simeng; You, Lixin; Qian, Sangni; Tang, Mengling; Wang, Jianbing; Chen, Kun; Jin, Mingjuan

doi:10.1002/cncr.33795

Cited by 106 publications

(77 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the cervical cancer screening rate is lower in Japan than in other countries. 19, 20 Thus, individuals should be encouraged to receive cervical cancer vaccination and cervical cancer screening.…”

Section: Discussionmentioning

confidence: 99%

Trends in pregnancy-associated cervical cancer in Japan between 2012 and 2017: A multicenter survey

Enomoto

Yoshihara

Kondo

et al. 2022

Preprint

View full text Add to dashboard Cite

Large-scale data on maternal and neonatal outcomes of pregnancy-associated cervical cancer in Japan are scarce, and treatment strategies have not been established. We conducted this multicenter retrospective observational study at 523 secondary/tertiary care hospitals in Japan to investigate the clinical features and trends in pregnancy-related cervical cancer treatments. We collected data for 290 patients with pregnancy-associated cervical cancer (during pregnancy, n=203; postpartum, n=87) diagnosed between January 1, 2012, and December 31, 2017. Of the 40 patients diagnosed at ≥22 gestational weeks, 34 (85.0%) were carefully followed until delivery without intervention. Of the 163 patients diagnosed at <22 gestational weeks, 111 and 52 patients continued and terminated their pregnancies, respectively. Although the termination rate increased with cervical cancer stage, 90 patients with stage IB1 disease had a variety of treatment options, including termination of pregnancy. When we divided the 59 stage IB1 patients who continued their pregnancy into four groups based on the primary treatment (strict follow-up, conization, trachelectomy, and neoadjuvant chemotherapy), there were no significant differences in progression-free or overall survival. The percentile of birth weight at delivery was smaller in the neoadjuvant chemotherapy group than in the strict follow-up group (P =.02). The full-term delivery rate was relatively higher in the trachelectomy group (35%) than in the other groups. In conclusion, treatment decisions, including pregnancy termination for pregnancy-associated cervical cancer, should be made after estimating the stage, with careful consideration of both maternal and fetal benefits. These findings will help in developing treatment guidelines for pregnancy-associated cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends in pregnancy-associated cervical cancer in Japan between 2012 and 2017: A multicenter survey

Enomoto

Yoshihara

Kondo

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“… 4 , 5 , 6 However, the number of patients admitted to the intensive care unit (ICU) has increased. 7 Results from a previous epidemiological study revealed an ICU admission rate of 5.2% within 2 years of a definite diagnosis of cancer. 8 Currently, identification of biomarkers for predicting the prognosis of cancer patients in the ICU is a hot research topic.…”

Section: Introductionmentioning

confidence: 96%

“…Overall cancer mortality has declined owing to advancement in techniques used for the early detection of tumors and the emergence of new treatment strategies 4–6 . However, the number of patients admitted to the intensive care unit (ICU) has increased 7 . Results from a previous epidemiological study revealed an ICU admission rate of 5.2% within 2 years of a definite diagnosis of cancer 8 .…”

Section: Introductionmentioning

confidence: 99%

Red blood cell distribution width‐to‐albumin ratio is associated with all‐cause mortality in cancer patients

Lu¹,

Long

Liu³

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background: Cancer causes a serious health burden on patients worldwide. Chronic low-level inflammation plays a key role in tumorigenesis and prognosis. However, the role of the red blood cell distribution width (RDW)-to-albumin (RA) ratio in cancer mortality remains unclear. Methods:In this retrospective cohort study, we collected clinical information from cancer patients from the Medical Information Mart for Intensive Care III (MIMIC-III) version 1.4 database and then calculated RA by dividing RDW by albumin concentration. The primary outcome was 30 days mortality, while secondary outcomes were 90 days and 1 year mortality. Next, we adopted Cox regression models to calculate hazard ratios (HR) together with 95% confidence intervals (CI) for all-cause mortalities associated with the RA ratio.Results: For 30 days mortality, the HR (95% CI) for the high RA ratio (≥5.51) was 2.17 [95CI% (1.87-2.51); p = <0.0001], compared with the low RA ratio (<5.51). In Model 2, we adjusted sex and age and obtained HR (95% CI) of 2.17 [95CI% (1.87-2.52); p = <0.0001] for the high RA ratio (≥5.51) group, compared to that in the low RA ratio (<5.51). In Model 3, adjusting for age, sex, anion gap, hematocrit, white blood cell count, congestive heart failure, SOFA, liver disease, and renal failure resulted in HR (95% CI) of 1. ; p = <0.0001] for the high RA ratio (≥5.51) relative to the low RA ratio (<5.51). We also analyzed common diseases in cancer patients but found no significant association. Conclusion:To the best of our knowledge, this is the first study demonstrating that increased RA ratio is independently associated with increased all-cause mortality in cancer patients.

show abstract

“… 2 Among the stages of CC, the International Federation of Gynecology and Obstetrics (FIGO) stage IIB–IVA accounts for more than 80% of new diagnoses in developing countries. 3 , 4 For these patients, external beam radiation therapy (EBRT) along with brachytherapy (BRT) and concomitant chemotherapy (CT) has been recommended as the paradigm of curative treatment based on a recent series of high level randomized controlled trials. 5–7 However, 25–75% of patients with stage IIB–IVA disease may develop tumor recurrence or distant metastasis, 8 which needs systemic therapy to palliate clinical symptoms and improve poor survival rates.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Analysis and Comparison of the 2014 and 2018 International Federation of Gynecology and Obstetrics Staging System on Overall Survival in Patients with Stage IIB-IVA Cervix Carcinoma

Song¹,

Xu²,

Shi³

et al. 2022

IJWH

View full text Add to dashboard Cite

Purpose This study aimed to assess the prognostic factors of overall survival (OS) in patients with stage IIB–IVA cervix carcinoma (CC) who underwent external beam radiation therapy (EBRT) and brachytherapy (BRT) and to compare the prognostic accuracy of the 2014 and 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system using the Surveillance, Epidemiology, and End Results (SEER) database. Methods Patients with a histopathological diagnosis of CC between 2004 and 2016 were included. The primary endpoint was OS. The prognostic significance for OS was analyzed by the Cox regression model. Prognostic accuracy in evaluating 3- and 5-year OS in different staging systems was evaluated using time-dependent receiver operating characteristic (tdROC) curves. Results A total of 2585 patients with stage IIB–IVA CC, staged according to the 2014 FIGO staging system, were included in the study. The 3- and 5-year OS rates were 63.9% and 56.6%, respectively, with a median OS of 98 months. Independent variables, such as older age at diagnosis, histological grades apart from well or moderately differentiated, large tumor size, advanced tumor stages classified according to the 2014 and 2018 FIGO staging systems and treatment without chemotherapy or unknown were associated with a worse OS. A tdROC analysis conducted using DeLong’s tests revealed no significant difference in the prediction of 3- and 5-year OS between the 2014 and 2018 FIGO staging systems ( P = 0.912 and 0.863, respectively). Conclusion Both 2014 and 2018 FIGO staging systems were strong prognostic factors for OS. No significant risk classification was observed for stage IIIC1 disease in the revised 2018 FIGO staging system for patients who underwent EBRT and BRT.

show abstract

Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years

Cited by 106 publications

References 52 publications

Trends in pregnancy-associated cervical cancer in Japan between 2012 and 2017: A multicenter survey

Trends in pregnancy-associated cervical cancer in Japan between 2012 and 2017: A multicenter survey

Red blood cell distribution width‐to‐albumin ratio is associated with all‐cause mortality in cancer patients

Prognostic Analysis and Comparison of the 2014 and 2018 International Federation of Gynecology and Obstetrics Staging System on Overall Survival in Patients with Stage IIB-IVA Cervix Carcinoma

Contact Info

Product

Resources

About